上海女性肺部5mm磨玻璃状结节上海吃什么蔬菜容易生结节,上海右上肺〈image85丿见实性小结节社大小约6mmx5mm严重吗,上海请问肺上有弯磨玻璃结节是好是坏,上海肾上腺肿瘤最佳治疗方法,上海眼肿瘤治疗费用大概多少,上海支气管扩张反复咳血怎么办,上海肺部感染寄生虫的早期症状

BEIJING, Oct. 27 (Xinhuanet) -- Virginia M. Rometty, 54, will succeed present IBM CEO Sam Palmisano to be the next chief executive at the start of 2012, the company announced Tuesday.This is unprecedented in the New York-based company's 100-year history, because Rometty, a senior vice president of IBM, will be its first female CEO.Since joining the company three decades ago, Ms. Rometty has contributed a lot to the giant I.T. Company.After graduating from Northwestern University with an undergraduate degree in computer science, she entered the company in 1981 as a systems engineer. In virtue of outstanding performance, she was quickly promoted to management.For the following 20 years, she worked with clients in banking, insurance, and telecommunications, to name a few.In 2002, Rometty caught Palmisano's attention when she helped integrate the 3.5 billion dollar acquisition of the big business consulting firm PricewaterhouseCoopers Consulting, IBM's largest deal ever at the time.Then she became senior vice president of the group and group executive for sales, marketing and strategy in 2009. Under her leading, the business in overseas emerging markets including China, India, Brazil and several African nations, has increased sharply.New York Times reported that such markets now accounted for 23 percent of IBM.’s revenue, up from 20 percent when she took over.“Ginni got it because she deserved it,” Mr. Palmisano told the New York Times. "Ginni" is an informal first name used by her friends and colleagues.The selection of Rometty for chief executive will make her the 17th female CEO in the Fortune 500 on the following January. Other prominent women who play the same role as Rometty include Indra Nooyi of PepsiCo, Ellen J. Kullman of DuPont, Meg Whitman of Hewlett-Packard, and so on.

WASHINGTON, Oct. 13 (Xinhua) -- U.S. researchers have corrected sickle cell disease in adult laboratory mice that had been bred to have the inherited blood disorder by activating production of a special blood component, according to a study published online Thursday in the journal Science.Sickle cell disease results from an abnormality in hemoglobin, the protein found in red blood cells that is responsible for transporting oxygen throughout the body. People living with sickle cell disease have two copies of an altered gene that produces sickle hemoglobin instead of normal adult hemoglobin. Sickle hemoglobin changes shape after releasing its oxygen, causing the red blood cell to become stiff, misshapen and sticky, and slowing blood flow to tissues. This process damages organs and causes pain.The study tested a new approach to increasing the production of a third form of hemoglobin -- fetal hemoglobin. Production of fetal hemoglobin predominates before birth, but turns off thereafter as adult hemoglobin production takes over. People with sickle cell disease are unable to make normal adult hemoglobin, and instead make sickle hemoglobin starting in infancy.An elevated level of fetal hemoglobin within the red blood cell reduces the tendency of sickle hemoglobin to change the shape of red blood cells. Considerable research has shown that the drug hydroxyurea increases production of fetal hemoglobin and reduces the number of pain crises and other complications of sickle cell disease in adults and children. However, not all patients respond well to hydroxyurea, and adverse side effects are a concern.The current study explores a more targeted approach to increasing fetal hemoglobin production. It builds upon earlier studies that discovered a protein called BCL11A normally suppresses the production of fetal hemoglobin soon after birth. The researchers viewed the BCL11A protein as a target for therapy and decided to see what would happen if they blocked production of the protein.The paper details how the research team silenced the mouse gene that produces the BCL11A protein in mice with sickle cell disease. Silencing the gene turned off production of the BCL11A protein and allowed the adult mice to continue to produce fetal hemoglobin. It appears to have eliminated disease symptoms without affecting other aspects of blood production."This discovery provides an important new target for future therapies in people with sickle cell disease," said Susan Shurin, acting director of the U.S. National Heart, Lung, and Blood Institute, which co-funded the study. "More work is needed before it will be possible to test such therapies in people, but this study demonstrates that the approach works in principle."Approximately 100,000 Americans live with sickle cell disease. It is most prevalent in people of African, Hispanic, Mediterranean, and Middle Eastern descent. There is no widely available cure for sickle cell disease. Bone marrow transplants have cured some patients, but the treatment is not without risk and most patients do not have relatives who can donate compatible and healthy bone marrow to them.

SAN FRANCISCO, Dec. 9 (Xinhua) -- Apple on Friday suffered a major setback in its global patent war, as a German court ruled over its copyright infringement battle in favor of Motorola Mobility.The German court ruled that Apple's iPhone and iPad infringe a Motorola patent and issued an injunction banning the import of iPhones and 3G-capable iPads into Germany.The dispute, one of Apple's several patent lawsuits around the world, is over a Motorola patent essential to GPRS. Motorola has been negotiating with Apple over licensing terms and conditions since 2007, and it will continue its efforts to resolve its global patent dispute as soon as practicable, said Motorola Mobility in a statement on Friday."We're going to appeal the court's ruling right away. Holiday shoppers in Germany should have no problem finding the iPad or iPhone they want," an Apple spokesman told tech news site AllThingsD.Apple is not too concerned about losing out in the Christmas shopping season as it has plenty of iPhones and iPads in Germany already, AllThingsD cited unidentified sources as saying.The ruling is against Apple's European sales company and only impacts its products sold in Germany. The German court also ruled that Motorola is entitled to a damages award.Apple can appeal the ruling to a higher court and request a stay of the injunction, according to a blog post of Florian Mueller, a U.S. patent expert who has been closely following patent lawsuits in the mobile industry.Mueller said should Apple make the appeal but the court declines the stay, Motorola must post a 100 million euro (around 134 million U.S. dollars) bond before the court will enforce the injunction.In August, Apple also filed a suit in Germany over the design of Motorola's tablet Xoom, which runs Google's Android system. But Apple did not make it clear whether it will seek to block the sales of Xoom in Europe.Also on Friday, Samsung won an appeal from the Australian High Court overturning a previous Apple victory that effectively banned Samsung from selling its Galaxy Tab in Australia.Based on claims of infringing Apple's patents, the Cupertino, California-based tech giant has been seeking court order to block Samsung's Galaxy line of mobile devices around the world.A German court issued an injunction in August, blocking Samsung from selling its Galaxy Tab 10.1 tablets across all European Union members, except for the Netherlands.On Thursday, Apple said it will appeal a San Jose, California judge's refusal to ban sales of Samsung 4G smartphones and Galaxy Tab 10.1 tablets in the United States.

BEIJING, Oct. 11 (Xinhuanet) -- Scientists have discovered that blind optimism is related to brain's frontal lobes which are associated with processing errors, according to a British study published Monday in the journal Nature Neuroscience.Scientists at the University College of London scanned brains of volunteers who were asked to estimate their personal likelihood of involving in negative events, like a divorce or cancer,  before and after given the average probability of these events occurring.They found that the volunteers who estimated lower probability (or the more optimistic ones) than the given one raised their estimates a little bit later while those estimated higher probability altered their estimates much more.Through the brain scanner, scientists saw there was less activity in the volunteers' frontal regions when the information given was worse than expected while more activity when the information was better than expected. It suggested that the more optimistic people neglected the negative predictions."The more optimistic we are, the less likely we are to be influenced by negative information about the future," said Dr. Tali Sharot, lead author of the study. He added being optimistic clearly had some benefits, "but it can also mean that we are less likely to take precautionary action, such as practising safe sex or saving for retirement. So why don't we learn from cautionary information?"